As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
Japan’s average price discrepancy rate between NHI and market prices is expected to shrink again this year, possibly falling into the 4% range, according to multiple wholesalers interviewed by Jiho. The average rate was 5.2% in last year’s drug price…
To read the full story
Related Article
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
BUSINESS
- Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
- Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan
November 18, 2025
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
- Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
- Dupixent 200 mg Pen Now Available in Japan: Sanofi
November 18, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…